Healthcare - Biotechnology - NASDAQ - US
$ 0.714
-0.833 %
$ 24.7 M
Market Cap
-0.24
P/E
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients.[ Read More ]
The intrinsic value of one OCEA stock under the base case scenario is HIDDEN Compared to the current market price of 0.714 USD, Ocean Biomedical, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart OCEA
FINANCIALS
0
REVENUE
-2.48 M
OPERATING INCOME
-958 K
NET INCOME
-747 K
OPERATING CASH FLOW
-2.1 M
INVESTING CASH FLOW
2.1 M
FINANCING CASH FLOW
0
REVENUE
-2.66 M
OPERATING INCOME
-14.1 M
NET INCOME
-1.13 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
0
FINANCING CASH FLOW
Balance Sheet Decomposition
Ocean Biomedical, Inc.
| Current Assets | 468 K |
| Cash & Short-Term Investments | 328 K |
| Receivables | 50 K |
| Other Current Assets | 89.7 K |
| Non-Current Assets | 110 M |
| Long-Term Investments | 110 M |
| PP&E | 0 |
| Other Non-Current Assets | 0 |
| Current Liabilities | 3.46 M |
| Accounts Payable | 325 K |
| Short-Term Debt | 2.15 M |
| Other Current Liabilities | 989 K |
| Non-Current Liabilities | 3.15 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 3.15 M |
EFFICIENCY
Earnings Waterfall
Ocean Biomedical, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 2.48 M |
| Operating Income | -2.48 M |
| Other Expenses | -1.52 M |
| Net Income | -958 K |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
0.54%
ROE
0.51%
ROA
-2.33%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Ocean Biomedical, Inc.
| Net Income | -958 K |
| Depreciation & Amortization | 1.52 M |
| Capital Expenditures | -3 |
| Stock-Based Compensation | 0 |
| Change in Working Capital | 1.74 M |
| Others | -79.3 K |
| Free Cash Flow | -747 K |
Wall Street Analysts Price Targets
Ocean Biomedical, Inc.
OCEA has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Ocean Biomedical, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
PROVIDENCE, Rhode Island, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on October 16, 2024, it received a Staff Determination Letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that on April 18, 2024, May 22, 2024, and August 19, 2024, Staff notified the Company that it did not comply with Nasdaq's filing requirements set forth in Listing Rule 5250(c)(1) (the “Rule”) because it had not filed its Form 10-K for the year ended December 31, 2024 (the “Form 10-K”), and its Forms 10-Q for the periods ended March 31, 2024 and June 30, 2024 (the “Forms 10-Q”), respectively. Based on its review and the materials submitted on June 17, 2024 and August 27, 2024, Staff granted the Company an exception until October 14, 2024, to regain compliance with the Rule. Upon further review, Staff determined that the Company did not meet the terms of the exception. Specifically, the Company has not filed the either its Form 10-K or Forms 10-Q as required by the Rule. The Company will appeal Staff's determination to a Hearings Panel (the “Panel”), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.
globenewswire.com
- 3 weeks ago
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.
This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as well as inflammatory and fibrotic diseases, offering a novel approach to treating these conditions. In addition, the license covers a patent pending for a molecular screening test for further the continuation of the program and the development of new YKL-40 inhibitors.
globenewswire.com
- 1 month ago
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
Ocean Biomedical's Anti-CHI3L1 patent coverage includes multiple methods of use for targeting a broad range of Cancers that include Lung Cancer, Glioblastoma, Prostate Cancer, Melanoma, and Breast Cancer
globenewswire.com
- 1 month ago
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention Platforms
Providence, RI, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA ) announced today that its Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been issued a key U.S. patent for his groundbreaking malaria therapeutic antibody discovery that targets PfGARP. Since publicizing news of his original research on PfGARP and its critical role in the malaria cycle in the Journal NATURE , Dr. Kurtis and his team have been working to deepen their understanding of how it naturally triggers the death of malaria parasites, and their control of that mechanism. Their expanded insights have already led to: 1.) a powerful vaccine candidate targeted for long term prevention of malaria infection; 2.) a therapeutic antibody candidate for short term malaria prevention; and 3.) a therapeutic small molecule drug candidate targeted to treat severe malaria, with potential to launch a whole new class of malaria medicines.
globenewswire.com
- 2 months ago
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
PROVIDENCE, Rhode Island, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on August 19, 2024, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the “SEC”).
globenewswire.com
- 2 months ago
3 Trending Biotech Penny Stocks
Biotech stocks are some of my favorite stocks to watch and invest in for a couple of reasons.
247wallst.com
- 2 months ago
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024
Providence, RI, June 05, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA ), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today congratulates its JV partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker presentation highlighting the first-ever human immunogenicity data from its novel checkpoint modifier immunotherapy for HBV functional cure (VRON-0200), at the EASL 2024 Congress (The European Association for the Study of the Liver), taking place in Milan, Italy from June 5 - 8.
globenewswire.com
- 5 months ago
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
PROVIDENCE, Rhode Island, May 30, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on May 22, 2024, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the “SEC”).
globenewswire.com
- 5 months ago
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease
Providence, RI, May 16, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA ) announced today that Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been granted a new patent for his malaria therapeutic antibody discoveries, targeted to both prevent malaria infection and treat severe malaria. Kurtis' novel approach can cause parasite death at a key stage in the malarial cycle, triggering programmed cell death through apoptosis. This expands patent protection for Dr. Kurtis' novel discoveries at a time when the most common strains of malaria are showing signs of growing resistance to current Artemisinin-based drugs.
globenewswire.com
- 6 months ago
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
PROVIDENCE, Rhode Island, April 24, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on April 18, 2024, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Annual Report on Form 10-K for the period ended December 31, 2023 (the “Form 10-K”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the “SEC”).
globenewswire.com
- 6 months ago
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
Providence, RI, March 28, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA ), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today congratulates its JV partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker oral presentation highlighting the first-ever human data from its novel checkpoint modifier immunotherapy for HBV functional cure (VRON-0200), at the 33 rd Annual Meeting of APASL (The Asian Pacific Association for the Study of the Liver), taking place in Kyoto, Japan from March 27 - 31.
globenewswire.com
- 7 months ago
Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting
Providence, RI, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA ), a biopharma company which endeavors to accelerate the development of compelling discoveries from top research scientists, today congratulates its joint venture partner , Virion Therapeutics, LLC, a clinical-stage biotechnology company developing T cell-based immunotherapies, for the acceptance of their abstract highlighting the first-ever human data from its novel checkpoint modifier immunotherapy for HBV functional cure, for late breaker oral presentation at the upcoming 33 rd Annual Meeting of APASL (The Asian Pacific Association for the Study of the Liver), taking place in Kyoto, Japan from March 27-31, 2024.
globenewswire.com
- 8 months ago
8. Profile Summary
Ocean Biomedical, Inc. OCEA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 24.7 M
Dividend Yield
0.00%
Description
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.
Contact
Room 325, 55 Claverick Street, Providence, RI, 02903
http://www.oceanbiomedical.com
IPO Date
Nov. 8, 2021
Employees
9
Officers
Ms. Jolie G. Kahn CPA, Esq.
Chief Financial Officer
Dr. Inderjote Kathuria M.B.A., M.D.
Chief Strategy Officer
Dr. Chirinjeev Baboo Kathuria M.B.A., M.D.
Founder & Executive Chairman of the Board
Dr. M. Michelle Berrey M.D., M.P.H.
Interim Chief Executive Officer & Director
Dr. Jonathan Kurtis M.D., Ph.D.
Founder, Chairman of Scientific Advisory Board & Director
Mr. Robert John Sweeney
Chief Accounting Officer & Assistant Secretary
Dr. Jack A. Elias M.D.
Founder, Chairman of Scientific Advisory Board & Independent Director